Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Dec;79(938):672-80.

Dr William Coley and tumour regression: a place in history or in the future

Affiliations

Dr William Coley and tumour regression: a place in history or in the future

S A Hoption Cann et al. Postgrad Med J. 2003 Dec.

Abstract

Spontaneous tumour regression has followed bacterial, fungal, viral, and protozoal infections. This phenomenon inspired the development of numerous rudimentary cancer immunotherapies, with a history spanning thousands of years. Coley took advantage of this natural phenomenon, developing a killed bacterial vaccine for cancer in the late 1800s. He observed that inducing a fever was crucial for tumour regression. Unfortunately, at the present time little credence is given to the febrile response in fighting infections-no less cancer. Rapidly growing tumours contain large numbers of leucocytes. These cells play a part in both defence and repair; however, reparative functions can also support tumour growth. Intratumoural infections may reactivate defensive functions, causing tumour regression. Can it be a coincidence that this method of immunotherapy has been "rediscovered" repeatedly throughout the centuries? Clearly, Coley's approach to cancer treatment has a place in the past, present, and future. It offers a rare opportunity for the development of a broadly applicable, relatively inexpensive, yet effective treatment for cancer. Even in cases beyond the reach of conventional therapy, there is hope.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Med Hist. 1990 Jul;34(3):294-310 - PubMed
    1. Clin Infect Dis. 2002 Feb 15;34(4):434-40 - PubMed
    1. Surg Oncol. 2002 Jun;11(1-2):77-83 - PubMed
    1. Pediatrics. 1999 Apr;103(4 Pt 1):783-90 - PubMed
    1. J R Coll Surg Edinb. 2000 Feb;45(1):1-16 - PubMed

MeSH terms

Substances

Personal name as subject